Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details the exercise of share options by specific individuals on December 1, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It strictly reports the acquisition of Ordinary Shares by directors and PDMRs under the GSK ShareSave Plan at an option price of £11.59 per share.
Important Facts for Investors
- Transaction Date: December 1, 2015.
- Transaction Type: Exercise of options granted on December 1, 2012, under the ShareSave Plan.
- Option Price: £11.59 per share.
- Participants and Share Counts:
- Sir Andrew Witty: 776 shares
- Mr R Connor: 776 shares
- Mr S Dingemans: 310 shares
- Mr D Redfern: 776 shares
- Mr P Thomson: 465 shares
- Dr P Vallance: 776 shares